Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiprodil drug-drug interaction study with carbamazepine and itraconazole
NCT06965881Phase 1Terminated
- Sponsor
- GRIN Therapeutics, Inc.
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of radiprodil in tuberous sclerosis complex (TSC), focal cortical dysplasia (FCD) and epilepsy (2 arms), sponsored by GRIN Therapeutics, Inc. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve from 0 to Last Quantifiable Concentration and 1 more. Started May 2025; status: terminated.
02
Drugs
radiprodil
03
Conditions
tuberous sclerosis complex (TSC)focal cortical dysplasia (FCD)epilepsy
Beyond the preview
Go deeper on NCT06965881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965881.